Thank you very much, Mr. Chair.
I want to thank everyone for coming. It's nice to see Marc-André Gagnon here with us again, because he's such an expert on so many things. I really respect his thinking and the work he's doing.
I want to ask a couple of questions.
We're talking about the compromise. I want to talk about the compromise text and the fact that the United States, the European Union, India and South Africa are having trouble coming to grips with getting this compromise text done.
First and foremost, the whole concept included more than just vaccines. We talk a lot about vaccines, but I think we need to talk about testing, tracking and surveillance. How do we know if it's 15 million or six million deaths? If you're not testing, tracking and surveilling, how do you know what cases you have? That's my first question.
The second one is, why are treatments being left out of this agreement? How does this compromise fail to address the non-IP components or trade secrets? What can we do to move this along? What can Canada do to get this compromise agreement passed? What are the stumbling blocks? Do any of you know?